These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 26336814)

  • 1. After 6years of intraperitoneal insulin administration IGF-I concentrations in T1DM patients are at low-normal level.
    van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
    Growth Horm IGF Res; 2015 Dec; 25(6):316-9. PubMed ID: 26336814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Effects of Intraperitoneal and Subcutaneous Insulin Administration on the GH-IGF-1 Axis in Type 1 Diabetes.
    van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
    J Clin Endocrinol Metab; 2016 Jun; 101(6):2493-501. PubMed ID: 27115061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report of a 7 year case-control study of continuous intraperitoneal insulin infusion and subcutaneous insulin therapy among patients with poorly controlled type 1 diabetes mellitus: favourable effects on hypoglycaemic episodes.
    van Dijk PR; Logtenberg SJ; Groenier KH; Gans RO; Bilo HJ; Kleefstra N
    Diabetes Res Clin Pract; 2014 Nov; 106(2):256-63. PubMed ID: 25305134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up.
    van Dijk PR; Logtenberg SJ; Groenier KH; Gans RO; Kleefstra N; Bilo HJ
    BMC Endocr Disord; 2014 Apr; 14():30. PubMed ID: 24708696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion.
    Hedman CA; Frystyk J; Lindström T; Oskarsson P; Arnqvist HJ
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):58-62. PubMed ID: 23865977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous intraperitoneal insulin infusion versus subcutaneous insulin therapy in the treatment of type 1 diabetes: effects on glycemic variability.
    van Dijk PR; Groenier KH; DeVries JH; Gans RO; Kleefstra N; Bilo HJ; Logtenberg SJ
    Diabetes Technol Ther; 2015 Jun; 17(6):379-84. PubMed ID: 25856045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal versus subcutaneous insulin therapy in the treatment of type 1 diabetes mellitus.
    van Dijk PR; Logtenberg SJ; Hendriks SH; Groenier KH; Feenstra J; Pouwer F; Gans RO; Kleefstra N; Bilo HJ
    Neth J Med; 2015 Nov; 73(9):399-409. PubMed ID: 26582805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.
    Lassmann-Vague V; Belicar P; Alessis C; Raccah D; Vialettes B; Vague P
    Diabet Med; 1996 Dec; 13(12):1051-5. PubMed ID: 8973887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Optimized Percutaneous Access System for CIPII.
    Garcia-Verdugo R; Erbach M; Schnell O
    J Diabetes Sci Technol; 2017 Jul; 11(4):814-821. PubMed ID: 28654300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion.
    Liebl A; Hoogma R; Renard E; Geelhoed-Duijvestijn PH; Klein E; Diglas J; Kessler L; Melki V; Diem P; Brun JM; Schaepelynck-Bélicar P; Frei T;
    Diabetes Obes Metab; 2009 Nov; 11(11):1001-8. PubMed ID: 19740082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiological effects of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: A systematic review and meta-analysis.
    Dirnena-Fusini I; Åm MK; Fougner AL; Carlsen SM; Christiansen SC
    PLoS One; 2021; 16(4):e0249611. PubMed ID: 33848314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexual dimorphism in growth and insulin-like growth factor-I in children with type 1 diabetes mellitus.
    Bizzarri C; Benevento D; Giannone G; Bongiovanni M; Anziano M; Patera IP; Cappa M; Cianfarani S
    Growth Horm IGF Res; 2014 Dec; 24(6):256-9. PubMed ID: 25175911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia.
    van Dijk PR; Logtenberg SJ; Gans RO; Bilo HJ; Kleefstra N
    Clin Endocrinol (Oxf); 2014 Oct; 81(4):488-97. PubMed ID: 25041605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients.
    Oskarsson PR; Lins PE; Backman L; Adamson UC
    Diabetes Metab; 2000 Apr; 26(2):118-24. PubMed ID: 10804326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intraperitoneal insulin versus subcutaneous insulin administration on sex hormone-binding globulin concentrations in patients with type 1 diabetes mellitus.
    Boering M; van Dijk PR; Logtenberg SJ; Groenier KH; Wolffenbuttel BH; Gans RO; Kleefstra N; Bilo HJ
    Endocr Connect; 2016 May; 5(3):136-42. PubMed ID: 27287189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of insulin therapy on IGF-1 level in children with new-onset type 1 diabetes mellitus: a comparison between DKA and non-DKA.
    Shiva S; Behbod H; Ghergherechi R
    J Pediatr Endocrinol Metab; 2013; 26(9-10):883-6. PubMed ID: 23729551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous Subcutaneous Insulin Infusion in Neonates and Infants Below 1 Year: Analysis of Initial Bolus and Basal Rate Based on the Experiences from the German Working Group for Pediatric Pump Treatment.
    Kapellen TM; Heidtmann B; Lilienthal E; Rami-Merhar B; Engler-Schmidt C; Holl RW
    Diabetes Technol Ther; 2015 Dec; 17(12):872-9. PubMed ID: 26509360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion.
    Wredling R; Liu D; Lins PE; Adamson U
    Diabete Metab; 1991; 17(5):456-9. PubMed ID: 1752346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.